Asymmetric total synthesis of (+)-fostriecin.
[structure: see text] The title compound, a potent protein phosphatase inhibitor and anticancer agent, was prepared by an efficient, multiconvergent asymmetric synthesis. Key transformations include a ring forming olefin metathesis leading to the alpha,beta-unsaturated lactone and creation of the triene moiety via Suzuki cross-coupling.
Reddy
Y Krishna
YK
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9038, USA.
Falck
J R
JR
D000475:Alkenes / Q000138:chemical synthesis* / Q000737:chemistry; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors*; D011090:Polyenes; D011753:Pyrones
D000475:Alkenes; D004791:Enzyme Inhibitors; D011090:Polyenes; D011753:Pyrones; D010749:Phosphoprotein Phosphatases; C040313:fostriecin